← board
LGVN
Longeveron Inc.distress 7/10 · high distress / dilution risk$0.64+2%today-63% from 52w high
Lead: hypoplastic left heart syndrome
Revenue
pre-revenue
Liquidity
$16M
Runway
0.9 yrs
Shares 1y
—
Price & events
+16.6% over 6M
CatalystRating changeDilutionFinancingdashed = today
+2.1%
1D
+4.4%
1W
-20.0%
1M
-34.4%
3M
+9.4%
6M
-63.2%
1Y
-78.0%
2Y
-99.0%
5Y
-99.1%
All
Overview
- Volume
- 20.77K
- 52 Week Range
- $0.48 – $1.74
- Float Shares
- 25.86M
- Short %
- 5.47%
- % Held by Insiders
- 9.32%
- % Held by Institutions
- 11.88%
- RVOL
- 0.08x
- Beta
- -0.36
Pipeline stages · 1 programs
Lomecel-B medicinal signaling cells
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-06-30 | Phase 2 | Lomecel-B medicinal signaling cellsrmatfast trackorphanrare pediatric | Hypoplastic Left Heart Syndrome | 40 | active not recruiting |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 6
- August 2026Estimated 45%readoutPhase 2laromestrocel · Top-line results from Phase 2b ELPIS II trialSEC 8-K
- 2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026trial initiationsecondaryPhase 2laromestrocel · Phase 2 pivotal registration trial initiationSEC 8-K
- 2026-03-10partnershipSecurities purchase agreement with investors for private placement of common stock and convertible preferred stock.SEC 8-K
- 2025-07-08fda agreementlaromestrocel · FDA cleared IND application for Phase 2 trial in pediatric DCMSEC 8-K
- July 28, 2024conferencedata presentationsecondaryPhase 2Lomecel-B · Full CLEAR MIND Phase 2a results presented at AAIC 2024.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-05-11Maxim GroupBuy → Hold
- 2026-05-04HC Wainwright & Co.Buy
- 2025-08-15Roth CapitalBuy
- 2025-03-21HC Wainwright & Co.Buy
- 2025-03-03HC Wainwright & Co.Buy
- 2024-12-05Roth MKMBuy
Competitors — hypoplastic left heart syndrome
- none identified
Recent news
- 2026-07-23Doctor With Over 30 Years' Experience Joins Longeveron Board - Stock Titan
- 2026-07-21Longeveron : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
- 2026-07-21LGVN Stock Slips After Hours As FDA Flags Concerns On Rare Heart Defect Trial Design - Stocktwits
- 2026-07-20Longeveron Enhances CEO Compensation and Retention Protections - TipRanks
- 2026-07-14Longeveron Inc. (LGVN) director files Form 3 showing no share holdings - Stock Titan
- 2026-07-14Longeveron (NASDAQ: LGVN) updates CEO severance and equity vesting - Stock Titan
- 2026-07-13Longeveron Inc. (LGVN) director Leah Cann reports no stock ownership - Stock Titan
- 2026-07-13Longeveron Inc. (LGVN) director reports zero share ownership - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.